UROONCO PCa chief editor Dr. Giancarlo Marra discusses the updated 2026 EAU Guidelines for prostate cancer with Prof. Philip Cornford and Prof. Derya Tilki.
While changes are limited this year, key points include refined risk stratification aligned with Cambridge groups, updated recommendations favouring enzalutamide plus ADT for high-risk recurrence, and emerging diagnostic tools like micro-ultrasound. In metastatic disease, emphasis has shifted toward personalised treatment, including BRCA testing and combination therapies. Greater focus is also placed on managing treatment-related complications, particularly bone health and cardiovascular risk, to improve long-term patient outcomes.